Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 3/20 | 0.47 |
| ▸ | CDK4 | P11802 | 7/20 | 0.44 |
| ▸ | CCND1 | P24385 | 4/20 | 0.44 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 3/20 | 0.41 |
| ▸ | WEE1 | P30291 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264405 | 0.80 | TTK (0.52) | BRD4CDK4CCND1TTKJAK2 | |
| SCHEMBL266000 | 0.79 | SRC (0.50) | EGFRINSRPDGFRBSRCKDR | |
| SCHEMBL265081 | 0.77 | MAPKAPK2 (0.53) | BRD4CDK4CCND1TTKFLT3 | |
| Hydrochloric Acid SCHEMBL4491420 | 0.74 | PLK1 (0.51) | BRD4CDK4CCND1JAK2CDK2 | |
| SCHEMBL264933 | 0.74 | EHMT2 (0.46) | INSRSRCKDR | |
| SCHEMBL264449 | 0.74 | BRD4 (0.56) | BRD4CDK4CCND1TTKJAK2 | |
| SCHEMBL263993 | 0.74 | CDK4 (0.45) | BRD4CDK4CCND1TTKAURKA | |
| SCHEMBL265485 | 0.73 | BRD4 (0.72) | FGFR4BRD4EGFRCDK2CCNK | |
| SCHEMBL264391 | 0.73 | TTK (0.50) | BRD4CDK4CCND1TTKJAK2 | |
| SCHEMBL265103 | 0.73 | BRD4 (0.48) | BRD4CDK4CCND1TTKCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604042-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | FGFR4 705/4885BRD4 156/4885CDK4 443/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | FGFR4 259/4885BRD4 142/4885CDK4 117/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | FGFR4 259/4885BRD4 142/4885CDK4 117/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | FGFR4 259/4885BRD4 142/4885CDK4 117/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | FGFR4 259/4885BRD4 142/4885CDK4 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.